Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

61.44
Delayed Data
As of 4:00pm ET
 +5.95 / +10.72%
Today’s Change
49.96
Today|||52-Week Range
137.89
-34.74%
Year-to-Date
Why Alnylam Pharmaceuticals, Inc. Jumped 10.7% on Friday
4:53pm / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy in July
Jun 25 / MotleyFool.com - Paid Partner Content
Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
10:58am / TheStreet.com - Paid Partner Content
'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
Jun 25 / TheStreet.com - Paid Partner Content
Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
Jun 29 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close55.49
Today’s open55.85
Day’s range53.56 - 61.64
Volume1,453,262
Average volume (3 months)998,945
Market cap$4.7B
Dividend yield--
Data as of 4:00pm ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-43.49%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book3.73

Competitors

 Today’s
change
Today’s
% change
CRLCharles River Labora...+0.86+1.04%
ICLRICON PLC+0.63+0.90%
PRXLPAREXEL Internationa...+0.59+0.94%
IONSIonis Pharmaceutical...+1.13+4.85%
Data as of 4:02pm ET, 07/01/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.25
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs